Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene T
Go back to Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene T| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 17.53 +0.57 (3.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.96 | 52 Week High | $63.73 | |||
| Open | $17.05 | 52 Week Low | $8.00 | |||
| Day High | $18.01 | P/E | N/A | |||
| Day Low | $17.05 | EPS | $-5.69 | |||
| Volume | 5,610,427 | |||||
